NicVAX/Placebo as an Aid for Smoking Cessation
Public ClinicalTrials.gov record NCT00836199. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation
Study identification
- NCT ID
- NCT00836199
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Nabi Biopharmaceuticals
- Industry
- Enrollment
- 1,000 participants
Conditions and interventions
Conditions
Interventions
- NicVAX vaccine Biological
- Placebo vaccine Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2009
- Primary completion
- Jun 30, 2011
- Completion
- Jun 30, 2011
- Last update posted
- May 8, 2012
2009 – 2011
United States locations
- U.S. sites
- 22
- U.S. states
- 18
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NicVAX Investigator | Tucson | Arizona | — | — |
| NicVAX Investigator | Los Angeles | California | — | — |
| NicVAX Investigator | Newport Beach | California | — | — |
| NicVAX Investigator | San Diego | California | — | — |
| NicVAX Investigator | Denver | Colorado | — | — |
| NicVAX Investigator | Farmington | Connecticut | — | — |
| NicVAX Investigator | Miami | Florida | — | — |
| NicVAX Investigator | St. Petersburg | Florida | — | — |
| NicVAX Investigator | Boise | Idaho | — | — |
| NicVAX Investigator | Lexington | Kentucky | — | — |
| NicVAX Investigator | Baltimore | Maryland | — | — |
| NicVAX Investigator | College Park | Maryland | — | — |
| NicVAX Investigator | Boston | Massachusetts | — | — |
| NicVAX Investigator | Minneapolis | Minnesota | — | — |
| NicVAX Investigator | Omaha | Nebraska | — | — |
| NicVAX Investigator | Rochester | New York | — | — |
| NicVAX Investigator | Raleigh | North Carolina | — | — |
| NicVAX Investigator | Portland | Oregon | — | — |
| NicVAX Investigator | Draper | Utah | — | — |
| NicVAX Investigator | Norfolk | Virginia | — | — |
| NicVAX Investigator | Seattle | Washington | — | — |
| NicVAX Investigator | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00836199, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 8, 2012 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00836199 live on ClinicalTrials.gov.